{"page_content": "2020 CORPORATE SOCIAL RESPONSIBILITY REPORT62\nDear Communities\nABOUT SERVE TRANSFORM ADVANCE REDEFINE ETHICS & COMPLIANCE REPORTING INDEX   \nENABLING EXTERNAL  \nRESEARCH  \nproposals. Specific therapeutic area research \ncommittees are responsible for the evaluation \nof the incoming proposals.\nDespite the impact of the COVID-19 pandemic \non conducting research studies, we continued \nto receive Externally Sponsored Research  \n(ESR) proposals that we reviewed, processed \nand executed contracts for, to accelerate data \ngeneration contributing to advancing patient \ncare. The evidence generated through our ESR \nprogram has been published in peer-reviewed \njournals and presented at international \ncongresses.\nThis is an exciting and rewarding time to be  \npart of Alexion. \nSincerely,\nSalah I joined Alexion in 2020 and immediately \nwent to work learning about the myriad \nof ways we\u2019re advancing research on rare \ndiseases and devastating conditions with \nclinicians fighting alongside patients on  \nthe frontlines. \nAlexion meets its commitment to advance \nscience in areas of unmet medical need by \nproviding either funding or clinical supplies, or \nboth, to independent and unsolicited research Salah Benyamina, \nGlobal Head of Medical  \nAffairs Excellence\nSalah, celebrating his son\u2019s wedding  \nwith homemade pastries\n6 Publications6 Publications\nSPREADING THE WORD\nData generated by Alexion-funded Externally \nSponsored Research studies have been submitted  \nand/or published in peer-reviewed journals and \npresented at international congresses, including  \nsix publications in 2020. \nDISCOVERY   \nPARTNERSHIPS  \nAlexion is committed to supporting \nacademic investigators and their work to \nadvance research and develop innovative, \nlife-changing medicines through our \ncollaborative Discovery Partnerships  \nprogram. An example is our support of \nresearchers at the Imagine Institute in \nFrance, where researchers are conducting \ngroundbreaking work on therapies for \nsickle cell disease.", "metadata": {"source": "NASDAQ_ALXN_2020.pdf", "page": 61, "parser": "pypdf", "split_method": "page", "run_time": "2024-05-29 08:35:04"}, "type": "Document"}